Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Establish the maximum tolerated dose (MTD) of the study drug.
Part 1, one year
Yes
United States: Food and Drug Administration
ARRAY-162-111
NCT00959127
August 2009
January 2013
Name | Location |
---|---|
MD Anderson Cancer Center | Houston, Texas 77030-4096 |
University of Michigan Comprehensive Cancer Center | Ann Arbor, Michigan 48109-0752 |
University of Colorado Cancer Center | Denver, Colorado 80262 |
Washington University School of Medicine | Saint Louis, Missouri 63110 |
Ohio State University | Columbus, Ohio 43210 |
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore, Maryland 21231 |
University of California, Los Angeles | Los Angeles, California |
Dana-Farber/Harvard Cancer Center | Boston, Massachusetts 02115 |
Sarah Cannon Research Institute | Nashville, Tennessee 37203 |
South Texas Accelerated Research Therapeutics | San Antonio, Texas 78229 |